FR2991167A1 - COSMETIC USE OF AN EXTRACT OF LAMINARIA OCHROLEUCA AND A FLOS-AQUAE APHANIZOMENON EXTRACT TO COMBAT THE SIGNS OF SKIN AGING - Google Patents

Abstract

The present invention relates to a cosmetic treatment method for decreasing and / or delaying the signs of aging of the skin, characterized in that an effective amount of an extract of Laminaria ochroleuca and an extract of Aphanizomenon flos is applied. -aquae, on the skin.

Description

The present invention relates to a cosmetic treatment process intended to reduce and / or delay the signs of aging of the skin. The present invention relates to a cosmetic treatment method for reducing and / or delaying the signs of aging of the skin. skin, characterized in that an effective amount of an extract of Laminaria ochroleuca and an extract of Aphanizomenon flos-aquae is applied to the skin. Women and men tend to want to look young for as long as possible and therefore seek to fade the marks of aging skin. Human skin consists of three compartments namely: a superficial compartment, the epidermis, the dermis, and a deep compartment the hypodermis. The epidermis is a keratinized stratified squamous epithelium. It consists mainly (90%) of keratinocytes, but also other cells (melanocytes and Langerhans cells), and is based on a basement membrane that separates it from the dermis. The progressive differentiation of basement membrane cells towards the surface of the epidermis is accompanied by a multitude of changes. The keratinocytes differentiate and migrate from the basal layer to the surface where they desquamate. The dermis is a connective tissue. Its architecture results from the arrangement and the interactions between the constituents of the extracellular matrix and the fibroblasts which ensure their synthesis and their degradation. Other cellular constituents are involved in the immune system (macrophages and mast cells) or are related to the presence of blood vessels (endothelial, muscle and nerve cells). The dermis constitutes the main mass of the skin. The dermis is divided into two layers, papillary and reticular. The dermis consists of collagen and elastic fibers as well as glycosaminoglycans and proteoglycans. These different structures form a complex network that plays a key role in the biomechanical properties of the skin. The hypodermis is the deepest and thickest compartment of the skin. It is invaginated in the dermis and is attached to the underlying dermis by collagen and elastin fibers. It consists essentially of a type of cells specialized in the accumulation and storage of fat, adipocytes. The adipocytes constituting the hypoderm are cells grouped into lobules separated by connective tissue. The hypodermis plays the role of energy reserve. The fats contained in the adipocytes can be put back into circulation, via the venous route, during an intense effort or during a deficiency in energy supply, and will be transformed into energy. The hypodermis participates in the mechanical properties of the tissue, as well as in thermoregulation, since the fat is a thermal insulator. The anatomical location of the hypodermis is clearly a sexual one. If the hypodermis is distributed throughout the body, it tends to accumulate above the waist, at the level of the belly and the shoulders in the man, and in the woman, below the belt at the level of the thighs, hips and buttocks. The mechanical properties of the skin in vivo depend on many physiopathological parameters and are influenced by different parameters as mentioned above. These parameters include age, sex, anatomical sites. At the tissue level, the mechanical properties are dependent on the organization (composition, density, assembly and architecture) of the extracellular matrix molecules of the dermis as well as the organization and density of adipose tissue (Pierard and Lapiere, Arch Dermatol Res 1977 Dec 27; 260 (3): 231-9; Hermanns-Le and a1, Exp Gerontol, 2001 Feb; 36 (2): 363-72). These properties can be altered under physiological or pathological conditions, especially under normal conditions during aging or photoaging during which the extracellular support matrix disorganizes. Disorders of the three classes of dermal molecules and the dermal-epidermal junction (JDE) are observed: collagens, elastic fibers and proteoglycans.

The patent application FR2900046 has described anti-aging compositions comprising a hydroxylated diphenylmethane derivative, these compositions may also include, among multiple active agents, an extract of Aphanizomenon flos-aquae as an agent acting on the inhibition of matrix metalloproteinases (MMPs) and thus the inhibition of collagen degradation, and an extract of Laminaria ochroleuca as an agent stimulating the synthesis of glycosaminoglycans. Unexpectedly, the inventors have demonstrated, in a reconstructed skin model, that the combination of a Laminaria ochroleuca extract and an Aphanizomenon flos-aquae extract makes it possible to increase the expression in a synergistic manner. lumicane and collagens IV and VII, while each of the extracts alone has little or no effect on the synthesis of these molecules. Collagens are a family of extracellular matrix proteins, most often present in fibrillar form. These proteins have the function of giving the tissues a mechanical resistance to stretching. Collagens IV and VII are major components of the basal lamina that separates the epithelial cells from the underlying dermis. Lumicane is a proteoglycan that regulates the assembly of collagen fibers.

The synergistic stimulation of the synthesis of these extracellular matrix molecules by the combination of a Laminaria ochroleuca extract and an extract of Aphanizomenon flos-aquae thus makes it possible to improve the cutaneous cohesion and the biomechanical quality of the skin. .

The invention thus relates to a cosmetic treatment method intended to reduce and / or delay the signs of aging of the skin, characterized in that an effective amount of an extract of Laminaria ochroleuca and an extract of Aphanizomenon is applied. flos-aquae, on the skin. The method according to the invention is particularly intended to reduce and / or delay the signs of photoaging of the skin. The photoaging of the skin is linked to the exposure of the skin to UV radiation, in particular UV-A and / or UV-B radiation. More specifically, the method according to the invention is intended to reduce and / or delay wrinkles and fine lines, and / or thinning of the skin, and / or loosening of the skin and / or improving the density of the skin. .

In the context of the present application, "loosening of the skin" refers to the relaxation of the skin, which is, for example, in the form of wilted skin, soft skin, or thinned skin. Looseness is one of the signs of skin aging and may be related to environmental stress (eg pollution, UV radiation, especially UV-A and / or UV-B), a change in the organization of the skin. density of the hypodermis (changes in body mass, pregnancy, obesity, cellulitis), drug treatment (eg corticosteroids) or disorganization of extracellular matrix constituents (eg, stretch marks, scars, pressure ulcers). The skin may be the skin of the face and / or the skin of the body, in particular the cleavage, the neck, or the skin of the hands. For carrying out the process according to the invention, the Laminaria ochroleuca extract and the Aphanizomenon flos-aquae extract are preferably formulated in a composition further comprising a cosmetically acceptable medium.

Laminaria ochroleuca extract Laminaria ochroleuca is a species of laminar, yellow-brown, which is known to fight oxidative stress and cellular aging and in particular to promote the synthesis of glycosaminoglycans (patent application EP1074262).

The Laminaria ochroleuca extract may in particular be obtained by a process as described in application EP1074262, and which comprises, for example, the steps of: - harvesting fresh algae, for example on the northern coasts of Brittany, washing them, grinding them, advantageously to a size of between 100 and 200 μm, removing cell debris by centrifugation, to obtain a first supernatant, fractionating the supernatant by acid precipitation, preferably at room temperature; hydrochloric acid, and by activated carbon adsorption, to obtain a second supernatant, - filtering the second supernatant (for example by means of a tangential filtration with a cutoff threshold of 1000 Daltons) until the filtrate has reached a concentration of glycine betaine, measured by HPLC, of 12.5 ± 2.5%. Preferably the Laminaria ochroleuca extract is the Laminaïne Marine® BG / PF extract marketed by the company BiotechMarine (Pontrieux, France) (INCI name Water / Butylene Glycol / Laminaria ochroleuca Extract). This extract comprises, by weight relative to the total weight of the extract, 14 to 20% active ingredient, 35 to 51% butylene glycol and 35 to 45% water. The extract of Laminaria ochroleuca is present in the composition according to the present invention in a content of 0.001 to 10%, preferably of 0.005 to 5%, and very preferably in a content of 0.01% to 3%. by weight of extract, relative to the total weight of the composition. The composition according to the invention can thus comprise, by weight relative to the total weight of the composition, from 0.00014 to 2%, preferably from 0.0007 to 1%, and very preferably from 0.0014 to 0, 6% active ingredient extracted from Laminaria ochroleuca. Aphanizomenon flos-aquae extract Aphanizomenon flos-aquae is a species of cyanobacteria found in Klamath Lake, Oregon (USA) and characterized by Renhui et al. (Hydrobiology, 438: 99-105, 2000, Taxonomic re-evaluation of Aphanizomenon-flos-aquae NH-5 based on morphology and 16S rRNA gene sequences). The Aphanizomenon flos-aquae extract may in particular be obtained by a process as described in the patent application WO 2004/066969, and which comprises, for example, the following stages: at least one maceration at a temperature of 25 to 50 ° C, preferably about 35 ° C, dried blue algae of the species Aphanizomenon flos-aquae in the presence of enzymes such as cellulases, pectinases and glucanases, for a period of ten minutes at 10 hours stirring, preferably about four hours with stirring; a liquid / solid separation by centrifugation, preferably under an acceleration of 5,000 to 10,000 g, and more preferably of approximately 9,000 g; a liquid / liquid separation by a membrane filtration process; drying and / or dilution in a solution containing specific adjuvants, for example sorbitol; - A possible specific separation of the various constituents thus extracted, for example by chromatography, the various substances obtained can be used alone or in mixture, depending on the desired effect. The drying step may as well be a conventional drying (heat) that drying by nebulization or lyophilization. By this method, the substances having a major activity on the skin and the hair are extracted, namely carotenoids, phycocyanins, amino acids, in particular methionine, lysine, proline and serine, and polysaccharides. The extract thus obtained is composed in particular of proteins (between 0.05 to 1% w / w (mass ratio)), vitamin B12 (between 0.003 to 0.05% w / w), Lysine (between 0.2 at 3% w / w), methionine (between 0.04 to 0.6% w / w), proline (between 0.15 to 2.5% w / w) and serine (between 0.15 to 2.5% w / w) The Aphanizomenon flos-aquae extract may be dissolved in an aqueous solution such as a water / sorbitol mixture.

Preferably the Aphanizomenon flos-aquae extract is Lanablue® extract available from Unipex Innovations Inc. (INCI name Sorbitol (and) Water (and) Algae extract). This extract contains 1% of active ingredient, by weight relative to the total weight of the extract. The Aphanizomenon flos-aquae extract is present in the composition according to the present invention in a content ranging from 0.001% to 20%, preferably from 0.01% to 6% by weight, and preferably from 0.1% to 6% by weight. % to 5% by weight, relative to the total weight of the composition. The composition according to the invention may thus comprise, by weight relative to the total weight of the composition, from 0.00001 to 0.2%, preferably from 0.0001 to 0.06%, and preferably from 0.001% to 0%. , 05% of active ingredient extracted from Aphanizomenon flos-aquae.

In the context of the present invention, the weight ratio of the Laminaria ochroleuca extract to the Aphanizomenon flos-aquae extract in the composition is preferably from 0.1 to 10, and more particularly from 0.5 at 5.

Galenic The combination of at least one extract of Laminaria ochroleuca and an extract of Aphanizomenon flos-aquae is formulated for administration preferably topically, that is to say containing a cosmetically acceptable medium, that is a environment compatible with the skin, the nails, the mucous membranes, the tissues, the scalp and / or the hair. The combination can be formulated in the form of a cosmetic composition, that is to say intended to be applied to a healthy skin to improve the aesthetics and especially comfort. Healthy skin is defined as the absence of pathologies such as infections, inflammation, erythema, or wounds such as a burn or a cut. However, in this definition, healthy skin does not mean skin in perfect condition. The cosmetic composition is thus formulated for application to the skin and comprises an extract of Laminaria ochroleuca and an extract of Aphanizomenon flos-aquae, said composition making it possible to reduce and / or delay the signs of aging of the skin. According to a preferred embodiment of the invention, the composition has a pH close to that of the skin, between 4 and 7. The composition according to the invention is advantageously intended for topical application (composition for topical use).

When applied topically, the cosmetic composition may be applied to the face, neck, scalp, mucous membranes and nails or any other skin area of the body including the hands and feet. By "acceptable physiological medium" is meant a medium that is compatible with the skin or the materials and / or the keratinous fibers of human beings, such as, for example, without limitation, the skin, the mucous membranes, the nails, the leather hairy and / or hair. Such a medium does not generate tingling, tightness or redness unacceptable to the user. This physiologically acceptable medium comprises water, optionally mixed or not with one or more organic solvents such as C 1 -C 5 alcohols, in particular ethanol, isopropanol, tert-butanol, n-butanol, polyols such as glycerine, propylene glycol, butylene glycol and polyol ethers.

The compositions according to the invention are especially in the form of aqueous, hydroalcoholic or oily solutions, dispersions of the lotion or serum type, anhydrous or oily gels, emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion. a fatty phase in an aqueous phase (O / W) or conversely (W / O), multiple emulsions (triple: W / H / E or H / E / H), suspensions or consistency emulsions soft, semi-solid or solid type cream, gel, especially aqueous, microemulsions, or lipid vesicles of ionic and / or nonionic type (liposomes, niosomes, oleosomes), or thin films, or micro -capsules, micro-particles. It is also possible to use a composition according to the invention in the form of a water and oil biphase. The amounts of the various constituents of the cosmetic compositions used according to the invention are those conventionally used in the fields under consideration. These compositions are prepared according to the usual methods. In addition, the compositions used according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. They may optionally be applied to the skin in the form of an aerosol. They may also be in solid form, for example in the form of a stick. In particular, the cosmetic composition may be in the form of a transparent gel. In particular, this transparent gel is characterized by the fact that it is obtained by combining the active agents with a homopolymer of a monomer containing a sulfonic group. More particularly, said gel contains from 0 to 1% of oil. The polymers comprising at least one monomer containing a sulfonic group, used in this type of transparent gel, are advantageously water-soluble or water-dispersible or swellable in water. The polymers used for this type of transparent gel are homopolymers that can be obtained from at least one ethylenically unsaturated monomer and with a sulfonic group, which can be in free form or partially or completely neutralized. Preferably, the polymers used for this type of transparent gel may be partially or completely neutralized with a mineral base (sodium hydroxide, potassium hydroxide, ammonia) or an organic base such as mono-, di- or triethanolamine, an aminomethylpropanediol, N-methylglucamine, basic amino acids such as arginine and lysine, and mixtures of these compounds. They are usually neutralized. The term "neutralized" in the present invention means polymers that are totally or substantially completely neutralized, that is to say neutralized to at least 90%.

These polymers generally have a number average molecular weight ranging from 1000 to 20,000,000 g / mol, preferably from 20,000 to 5,000,000 and even more preferably from 100,000 to 1,500,000 g / mol. These polymers according to the invention may be crosslinked or non-crosslinked.

The monomers containing the sulfonic group of the polymer used in these transparent gels are chosen in particular from vinylsulfonic acid, styrenesulphonic acid, (meth) acrylamido (C 1 -C 22) alkylsulphonic acids, N- (C 1 -C 22) alkyl- ( meth) acrylamido (C1-C22) alkylsulfonic acid such as undecyl-acrylamidomethanesulfonic acid, as well as their partially or completely neutralized forms, and mixtures thereof. According to a preferred embodiment of the invention, the monomers containing a sulphonic group are chosen from (meth) acrylamido (C 1 -C 22) alkylsulphonic acids such as, for example, acrylamido-methanesulfonic acid, acrylamido acid and ethanesulfonic acid, acrylamido-propanesulfonic acid, 2-acrylamido-2-methylpropanesulfonic acid, 2-methacrylamido-2-methylpropanesulfonic acid, 2-acrylamido-n-butane sulfonic acid, 2-acrylamido-2,4,4-trimethylpentanesulfonic acid, 2-methacrylamido-dodecylsulfonic acid, 2-acrylamido-2,6-dimethyl-3-heptanesulfonic acid, and as their partially or totally neutralized forms, and their mixtures.

More particularly, 2-acrylamido-2-methylpropanesulfonic acid (AMPS) and its partially or completely neutralized forms are used. As other polymers suitable for this type of gel, mention may be made in particular of the crosslinked and neutralized homopolymer of 2-acrylamido-2-methylpropanesulphonic acid, marketed by the company Clariant under the trademark "Hostacerin® AMPS" (name CTFA: ammonium polyacryldimethyltauramide, INCI name: Ammonium polyacryloyl dimethyl taurate The monomer homopolymer containing a sulfonic group may be present in a transparent gel in an active material content ranging, for example, from 0.05 to 5% by weight, preferably ranging from from 0.1 to 5% by weight, preferably ranging from 0.05 to 2% by weight, for example from 0.1 to 0.4%, especially 0.25% by weight relative to the total weight of the composition When the composition used according to the invention, whatever its nature, comprises an oily phase, this phase preferably contains at least one oil and may further contain other fatty substances.

As oils that may be used in the cosmetic composition, mention may be made for example of: hydrocarbon-based oils of animal origin, such as perhydrosqualene; hydrocarbon-based oils of vegetable origin, such as liquid triglycerides of fatty acids containing from 4 to 10 carbon atoms, for instance triglycerides of heptanoic or octanoic acids or, for example, sunflower, corn or soybean oils, squash, grape seed, sesame, hazelnut, apricot, macadamia, arara, sunflower, castor oil, avocado, triglycerides of caprylic / capric acids such as those sold by Stearineries Dubois or those sold under the names Miglyol 810, 812 and 818 by the company Dynamit Nobel, jojoba oil, shea butter oil; esters and synthetic ethers, in particular of fatty acids, such as the oils of formulas R 1 COOR 2 and R 1 OR 2 in which R 1 represents the residue of a fatty acid comprising from 8 to 29 carbon atoms, and R 2 represents a hydrocarbon-based chain, branched or unbranched, containing from 3 to 30 carbon atoms, such as, for example, purcellin oil, isononyl isononanoate, isopropyl myristate, 2-ethylhexyl palmitate, octyl-2 stearate dodecyl, octyl-2-dodecyl erucate, isostearyl isostearate; hydroxylated esters such as isostearyl lactate, octyl hydroxystearate, octyldodecyl hydroxystearate, diisostearyl malate, triisocetyl citrate, heptanoates, octanoates, decanoates of fatty alcohols; polyol esters, such as propylene glycol dioctanoate, neopentyl glycol diheptanoate and diethylene glycol diisononanoate; and pentaerythritol esters such as pentaerythrityl tetraisostearate; linear or branched hydrocarbons of mineral or synthetic origin, such as paraffin oils, volatile or not, and their derivatives, petroleum jelly, polydecenes, hydrogenated polyisobutene such as parleam oil; fatty alcohols having from 8 to 26 carbon atoms, such as cetyl alcohol, stearyl alcohol and their mixture (cetylstearyl alcohol), octyldodecanol, 2-butyloctanol, 2-hexyldecanol, 2-undecylpentadecanol, oleic alcohol or linoleic alcohol; partially fluorinated hydrocarbon oils and / or silicone oils such as those described in document JP-A-2-295912; silicone oils such as volatile or non-volatile polymethylsiloxanes (PDMS) with a linear or cyclic silicone chain, which are liquid or pasty at room temperature, in particular cyclopolydimethylsiloxanes (cyclomethicones) such as cyclohexasiloxane; polydimethylsiloxanes comprising alkyl, alkoxy or phenyl groups, during or at the end of the silicone chain, groups having from 2 to 24 carbon atoms; phenyl silicones such as phenyltrimethicones, phenyldimethicones, phenyltrimethylsiloxydiphenylsiloxanes, diphenyldimethicones, diphenylmethyldiphenyltrisiloxanes, 2-phenylethyltrimethylsiloxysilicates, and polymethylphenylsiloxanes; - their mixtures. The term "hydrocarbon-based oil" in the list of oils mentioned above, any oil predominantly comprising carbon and hydrogen atoms, and optionally ester, ether, fluoro, carboxylic acid and / or alcohol groups.

The other fatty substances that may be present in the oily phase are, for example, fatty acids containing from 8 to 30 carbon atoms, such as stearic acid, auric acid, palmitic acid and oleic acid; waxes such as lanolin, beeswax, carnauba or candelilla wax, paraffin waxes, lignite waxes or microcrystalline waxes, ceresin or ozokerite, synthetic waxes such as polyethylene waxes, waxes Fischer-Tropsch; silicone resins such as trifluoromethyl-C1-4-alkyldimethicone and trifluoropropyldimethicone; and silicone elastomers such as the products sold under the names "KSG" by the company Shin-Etsu, under the names "Trefil", "BY29" or "EPSX" by the company Dow Corning or under the names "Gransil" by the company Grant Industries. These fatty substances may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example of consistency or texture. According to a particular embodiment, the cosmetic composition is a water-in-oil (W / O) or oil-in-water (O / W) emulsion. The proportion of the oily phase of the emulsion may range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition. The emulsions generally contain at least one emulsifier chosen from amphoteric, anionic, cationic or nonionic emulsifiers, used alone or as a mixture, and optionally a co-emulsifier. The emulsifiers are suitably selected according to the emulsion to be obtained (W / O or O / W). The emulsifier and the co-emulsifier are generally present in the composition, in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.

For the W / O emulsions, examples of emulsifiers that may be mentioned include dimethicone copolyols such as the mixture of cyclomethicone and dimethicone copolyol, sold under the name "DC 5225 C" by Dow Corning, and alkyldimethicone copolyols such as Laurylmethicone copolyol sold under the name "Dow Corning 5200 Formulation Aid" by the company Dow Corning and Cetyl dimethicone copolyol sold under the name Abil® EM 90 by Goldschmidt.

It is also possible to use, as surfactant of W / O emulsions, a crosslinked solid elastomeric organopolysiloxane comprising at least one oxyalkylene group, such as those obtained according to the procedure of Examples 3, 4 and 8 of US Pat. No. 5,412,004 and examples US-A-5,811,487, especially the product of Example 3 (synthetic example) of US-A-5,412,004. and such as that sold under the reference KSG 21 by Shin Etsu. Other types of KSG marketed by Shin Etsu can also be used, such as KSG-16. For O / W emulsions, mention may be made, for example, as emulsifiers, of nonionic emulsifiers such as oxyalkylenated (more particularly polyoxyethylenated) fatty acid esters of glycerol; oxyalkylenated fatty acid and sorbitan esters; oxyalkylenated fatty acid esters (oxyethylenated and / or oxypropylenated); oxyalkylenated fatty alcohol ethers (oxyethylenated and / or oxypropylenated); sugar esters such as sucrose stearate; and mixtures thereof such as the mixture of glyceryl stearate and PEG-40 stearate. In known manner, the cosmetic composition may also contain adjuvants customary in the cosmetic or dermatological field, such as hydrophilic or lipophilic gelling agents, preservatives, solvents, perfumes, fillers, UV filters, bactericides, odor, dyestuffs, plant extracts, salts, antioxidants, basic agents, acids, nonionic, anionic, cationic surfactants.

The amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into the lipid vesicles. As fillers which can be used in the composition of the invention, mention may be made, for example, besides pigments, silica powder, a colloidal amorphous silica; talcum; polyamide particles and in particular those sold under the name ORGASOL by the company Atochem; polyethylene powders; micro-spheres based on acrylic copolymers, such as those made of ethylene glycol dimethacrylate / lauryl methacrylate copolymer sold by Dow Corning under the name Polytrap; expanded powders such as hollow microspheres and in particular the microspheres sold under the name Expancel by the company Kemanord Plast or under the name Micropearl F 80 ED by the company Matsumoto; silicone resin microbeads such as those sold under the name Tospearl by the company Toshiba Silicone; and their mixtures. These fillers may be present in amounts ranging from 0 to 20% by weight and preferably from 1 to 10% by weight relative to the total weight of the composition. As hydrophilic or lipophilic gelling agents, there may be mentioned in particular carbopol, luvigel, Hostacerin AMPS, Simulgel, Sepigel-type acrylamide gelling agents such as Sepigel 305® from Seppic, xanthan gums, guar gums and cellulose gums, alginates and mixtures thereof. We can also mention hectorites. Antioxidants that may be mentioned include polyphenols, tannic acid, epoigallocathechins and natural extracts containing them, anthocyanins, rosemary extracts, olive leaf extracts, green tea, resveratrol and its derivatives. derivatives, Pycnogenol, ergothineine, N acetylcysteine, biotin, chelants, idebenone, plant extracts such as Pronalen Bioprotect TM from Provital, antiradicals such as vitamin E, co enzyme 010, bioflavonoids , SOD, phytantriol, lignans, melatonin, pidolates, glutathione. According to a preferred embodiment, the composition used according to the invention contains at least one UV filter (or sunscreen) which may be a chemical filter or a physical filter or a mixture of such filters. By way of illustration and in a nonlimiting manner, mention may be made of the following families (the names correspond to the CTFA nomenclature of the filters): anthranilates, in particular menthyl anthranilate; benzophenones, in particular benzophenone-1, benzophenone-3, benzophenone-5, benzophenone-6, benzophenone-8, benzophenone-9, benzophenone-12, and preferentially benzophenone-2 (oxybenzone), or Benzophenone-4 (Uvinul MS40 available from BASF); benzylidenecamphers, in particular 3-benzylidene camphor, benzylidenecamphosulfonic acid, camphor benzalkonium methosulphate, polyacrylamidomethylbenzylidene camphor, terephthalylidene di-camphorsulfonic acid, and preferentially 4-methylbenzylidene camphor (Eusolex 6300 available). at Merck); benzimidazoles, in particular benzimidazilate (Neo Heliopan AP available from Haarmann and Reimer), or phenylbenzimidazole sulfonic acid (Eusolex 232 available from Merck); benzotriazoles, in particular trisiloxane drometzol, or methylene bis-benzotriazolyltetramethylbutylphenol (Tinosorb M available from Ciba); cinnamates, in particular cinoxate, DEA methoxycinnamate, diisopropyl methylcinnamate, dimethoxycinnamate glyceryl ethylhexanoate, isopropyl methoxycinnamate, isoamyl cinnamate, and preferably ethocrylene (Uvinul N35 available from BASF), octyl methoxycinnamate (Parsol MCX available from Hoffmann La Roche), or octocrylene (Uvinul 539 available from BASF); dibenzoylmethanes, especially butyl methoxydibenzoylmethane (Parsol 1789); imidazolines, in particular ethylhexyl dimethoxybenzylidene dioxoimidazoline; PABAs, in particular ethyl dihydroxypropyl PABA, ethylhexyldimethyl PABA, glyceryl PABA, PABA, PEG-25 PABA, and preferentially diethylhexylbutamido-triazone (Uvasorb HEB available from 3V Sigma), ethylhexyltriazone (Uvinul T150 available from BASF), or ethyl PABA (benzocaine); salicylates, especially dipropylene glycol salicyclate, ethylhexyl salicylate, homosalate, or TEA salicylate; triazines, in particular anisotriazine (Tinosorb S available from Ciba); trisiloxane drometrizole, zinc oxide, titanium dioxide, zinc oxide, iron, zirconium, cerium coated or uncoated. The amount of filters depends on the desired end use. It may range, for example, from 1 to 20% by weight and better still from 2 to 10% by weight relative to the total weight of the composition. The cosmetic compositions may be applied directly to the skin or, alternatively, to occlusive or non-occlusive cosmetic or dermatological carriers intended to be applied in a localized manner to the skin.

The support can be an "occlusive" support. By way of example, the support consists of a thermoplastic material chosen from high and low density polyethylenes, polypropylenes, polyvinyl chlorides, copolymers of ethylene and vinyl acetate, polyesters and polyurethanes. , or a complex of such materials. These materials may also be present in laminated form with at least one sheet of metal such as aluminum foil. The support layer may be of any suitable thickness which will provide the desired support and protection functions. Preferably, the thickness of the support layer is from about 20 μm to about 1.5 mm. Advantageously, the support layer is sufficiently flexible so as to perfectly fit the profile of the skin, and not to cause the user, a feeling of discomfort. Preferably, however, the carrier is "non-occlusive". In the latter case, it is advantageous to use a support consisting of a paper, a porous or perforated thermoplastic material, a woven fabric, a nonwoven fabric or a perforated nonwoven fabric. According to another embodiment, said compositions for use according to the invention can be combined with compositions administered orally, containing additional cosmetic active agents with a beneficial effect on the appearance of the skin, such as, for example, active ingredients. additives to combat the signs of skin aging or additional active ingredients to fight against oily skin. Additional active ingredients The composition according to the invention may further contain other active agents, and in particular at least one compound chosen from: moisturizing agents; depigmenting agents; anti-aging / anti-wrinkle agents (anti-glycation agents; NO-synthase inhibitors; agents stimulating the synthesis of dermal or epidermal macromolecules and / or preventing their degradation; agents stimulating the proliferation of fibroblasts and / or keratinocytes or stimulating differentiation of keratinocytes; muscle relaxants); agents having a restructuring effect of the cutaneous barrier function; agents promoting the maturation of the horny envelope; agents promoting cutaneous microcirculation; agents stimulating cellular energy metabolism of cells; tensors; antioxidants; anti-pollution and / or anti-radical agents, desquamating agents, sunscreens, and mixtures thereof. By "moisturizing agent" is meant: - either a compound acting on the barrier function, in order to maintain the hydration of the stratum corneum, or an occlusive compound. There may be mentioned ceramides, sphingoid-based compounds, lecithins, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols (stigmasterol, R-sitosterol, campesterol), essential fatty acids, 1-2 diacylglycerol, 4-chromanone, pentacyclic triterpenes such as ursolic acid, petrolatum and lanolin; or a compound directly increasing the water content of the stratum corneum, such as thralose and its derivatives, hyaluronic acid and its derivatives, glycerol, pentanediol, sodium pidolate, serine, xylitol, lactate sodium, glycerol polyacrylate, ectoin and its derivatives, chitosan, oligo- and polysaccharides, cyclic carbonates, N-lauroyl pyrrolidone carboxylic acid, and Na-benzoyl-L-arginine; or an activating compound for sebaceous glands such as DHEA, its 7-oxidized and / or 17-alkylated derivatives, sapogenins and vitamin D and its derivatives. The "depigmenting agents" that may be incorporated into the composition according to the present invention comprise, for example, the following compounds: kojic acid; ellagic acid; arbutin and its derivatives such as those described in EP-895,779 and EP-524,109; hydroquinone; aminophenol derivatives such as those described in applications WO 99/10318 and WO 99/32077, and in particular N-cholesteryloxycarbonyl-para-aminophenol and N-ethyloxycarbonyl-para-aminophenol; iminophenol derivatives, in particular those described in application WO 99/22707; L-2-oxothiazolidine-4-carboxylic acid or procysteine, as well as its salts and esters; ascorbic acid and its derivatives, especially ascorbyl glucoside; and plant extracts, in particular licorice, mulberry and skullcap, without this list being limiting. By "anti-glycation agent" is meant a compound that prevents and / or decreases the glycation of skin proteins, in particular dermal proteins such as collagen. Examples of anti-glycation agents are plant extracts of the family Ericaceae, such as a bilberry extract (Vaccinium angustifolium); ergothioneine and its derivatives; and hydroxystilbenes and their derivatives, such as resveratrol and 3,3 ', 5,5'tetrahydroxystilbene. Examples of "NO synthase inhibitors" that are suitable for use in the present invention include, in particular, a plant extract of the Vitis vinifera species which is marketed in particular by Euromed under the name Leucocyanidines of extra grapes, or by the company Indena under the name Leucoselect®, or finally by the company Hansen under the name Grape marc extract; a plant extract of the species Olea europaea which is preferably obtained from olive leaves and is especially marketed by VINYALS in the form of dry extract, or by Biologia & Technologia under the trade name Eurol BT ; and an extract of a plant of the Gingko biloba species which is preferably a dry aqueous extract of this plant sold by Beaufour under the trade name Ginkgo biloba standard extract. Among the "agents stimulating the macromolecules of the dermis or preventing their degradation", mention may be made of those which act: either on the synthesis of collagen, such as extracts of Centella asiatica; asiaticosides and derivatives; ascorbic acid or vitamin C and its derivatives; synthetic peptides such as iamin, the biopeptide CL or palmitoyloligopeptide marketed by SEDERMA; peptides extracted from plants, such as the soy hydrolyzate marketed by the company Coletica under the trade name Phytokine®; and plant hormones such as auxins and lignans. or on the synthesis of elastin, such as the extract of Saccharomyces Cerivisiae sold by the company LSN under the trade name Cytovitin®; and the algae extract Macrocystis pyrifera marketed by SECMA under the trade name Kelpadelie®; or on the synthesis of glycosaminoglycans, such as the product of fermentation of milk with Lactobacillus vulgaris, sold by BROOKS under the trade name Biomin yogourth®; the extract of the brown alga Padina pavonica marketed by ALBAN MÜLLER under the trade name HSP3®; and the Saccharomyces cerevisiae extract available in particular from the company Silab under the trade name Firmalift® or from the company LSN under the trade name Cytovitin®; or on the synthesis of fibronectin, such as the Saline zooplankton extract marketed by Seporga under the trade name GP4G®; yeast extract available in particular from ALBAN MÜLLER under the trademark Drieline®; and the palmitoyl pentapeptide marketed by SEDERMA under the trade name Matrixil®; or on the inhibition of metalloproteinases (MMPs) such as, more particularly, MMPs 1, 2, 3, 9. It is possible to cite: retinoids and derivatives, oligopeptides and lipopeptides, lipoamino acids, marketed malt extract by the company COLETICA under the trade name Collalift®; extracts of blueberry or rosemary; lycopene; isoflavones, their derivatives or plant extracts containing them, in particular extracts of soya (marketed for example by the company Ichimaru PHARCOS under the trade name Flavosterone SB®), red clover, flax, kakkon or sage; or on the inhibition of serine proteases such as leukocyte elastase or cathepsin G. Mention may be made of: the peptide extract of leguminous seeds (Pisum sativum) marketed by the company LSN under the trade name Parelastyl®; heparinoids; and pseudodipeptides such as {2- [acetyl- (3-trifluoromethyl-phenyl) -amino] -3-methyl-butyrylamino} -acetic acid. Among the "active agents stimulating epidermal macromolecules", such as fillagrine and keratins, there may be mentioned in particular the lupine extract marketed by SILAB under the trade name Structurine®; the extract of Fagus sylvatica beech buds marketed by Gattefosse under the trade name Gatuline®; and the Saline zooplankton extract sold by Seporga under the trade name GP4G®. The "fibroblast proliferation stimulating agents" that can be used in the composition according to the invention may, for example, be chosen from plant proteins or polypeptides, extracted especially from soybeans (for example a soybean extract marketed by LSN under the name Eleseryl SH). -VEG 8® or sold by the company SILAB under the trade name Raffermine®); and plant hormones such as giberrellins and cytokinins. "Agents stimulating the proliferation of keratinocytes", usable in the composition according to the invention, include retinoids such as retinol and its esters, including retinyl palmitate; phloroglucinol; nut cake extracts sold by the company GATTEFOSSE; and extracts of Solanum tuberosum marketed by SEDERMA. "Agents stimulating the differentiation of keratinocytes" include, for example, minerals such as calcium; the lupine extract marketed by SILAB under the trademark Photopréventine®; sodium beta-sitosteryl sulphate marketed by Seporga under the trade name Phytocohesine®; and the corn extract marketed by SOLABIA under the trade name Phytovityl®; and lignans such as secoisolariciresinol. The composition according to the invention may comprise "dermo-decontracting agents", among which mention may in particular be made of alverine and its salts, in particular alverine citrate, sapogenins such as diosgenin and the natural extracts containing them ( such as extracts of Wild Yam), certain secondary and tertiary carbonyl amines, organic or inorganic metal salts, in particular manganese gluconate, adenosine, and the hexapeptide argireline R marketed by LIPOTEC. There may also be mentioned certain perfume compositions with a dermo-decontracting effect. As "agent having a restructuring effect of the skin barrier", there may be mentioned an extract of Thermus thermophilus such as Sederma Venuiteane®, an extract of wild yam rhizome (Dioscorea villosa) such as Actigen Y®. Active Organics, plankton extracts such as Secma's omega plancton®, yeast extracts such as Coletica's Relipidium®, a chestnut extract such as Silab's Recoverine®, a cedar bud extract such as Gatuline Zen Gattefossé ®, Degussa Phytosphingosine SLC, Seppic Aquaxyl ®, Coletica Lipidessence ®. There may also be mentioned ceramides and derivatives, compounds based on sphingoids, glycosphingolipids, phospholipids, cholesterol and its derivatives, phytosterols, essential fatty acids, diacylglycerol, 4-chromanone and chromon derivatives, the vaseline, lanolin, shea butters, cocoa butter, lanolin, etc. As preferred additional agents promoting the cutaneous barrier function, an extract of Thermus thermophilus, an extract of wild yam rhizome (dioscorea villosa), will be mentioned. yeast extract, chestnut extract, cedar bud extract and mixtures thereof.

As "agents promoting the maturation of the horny envelope", it will be possible to use, in the compositions of the invention, agents which mediate the maturation of the horny envelope, which deteriorates with age and induces a decrease in of transglutaminase activity. There may be mentioned, for example, urea and its derivatives and in particular Hydrovance® from National Starch and the other active agents mentioned in L'OREAL application FR2877220. As "agents promoting cutaneous microcirculation", it is possible to combine in the compositions of the invention agents acting on the cutaneous microcirculation in order to avoid dulling of the complexion and / or the formation of the pockets, for example an extract of black tea such as Sederma Kombuchka, Pycnogenol, Manganese Gluconate (Givobio GMn Seppic), Indena Visnadine, Lupine Extract (Silab Eclaline), Epine 100 Laboratories Cadene, an extract from bigarade flower (ilab remodulin), vitamin P and its derivatives such as Permethol Sochibios and other extracts (ruscus, chestnut, ivy, ginseng, sweetclover ...) and also caffeine, escin hesperitin laurate, dextran sulphate, nicotinate and derivatives, lysine and derivatives (such as Asparlyne of Solabia). As preferred additional agents promoting cutaneous microcirculation, mention may be made of Kombuchka, manganese gluconate and vitamin P and its derivatives. By "agents stimulating the energetic metabolism of the cells", it is also possible to associate active agents stimulating the energetic metabolism which is slowed down during aging, among which mention may be made of biotin, an extract of Saccharomyces cerevisaie such as Phosphovital® from Sederma, Physiogenyl® from Solabia, a mixture of zinc gluconate, copper and magnesium such as Sepitonic M3® from Seppic. By "tensing agent" is meant a compound capable of exerting traction on the skin. As "antioxidant" agents, there may be mentioned in particular tocopherol and its esters, in particular tocopherol acetate; BHT, Tinoguard TT and BHA. There may also be mentioned polyphenols, tannic acid, epoigallocathechins and natural extracts containing them, anthocyanins, rosemary extracts, olive leaf extracts, green tea, resveratrol and its derivatives, Pycnogenol , ergothineine, N acetylcysteine, biotin, chelants, idebenone, plant extracts such as Pronalen Bioprotect TM from Provital, antiradicals such as vitamin E, coenzyme Q10, bioflavonoids, SOD, phytantriol, lignans, melatonin, pidolates, glutathione.

By the term "anti-pollution agent" is meant any compound capable of trapping ozone, mono- or polycyclic aromatic compounds such as benzopyrene and / or heavy metals such as cobalt, mercury, cadmium and / or nickel. By "anti-radical agent" is meant any compound capable of trapping free radicals. As "ozone trapping agents" that may be used in the composition according to the invention, mention may be made in particular of vitamin C and its derivatives including ascorbyl glucoside; phenols and polyphenols, in particular tannins, ellagic acid and tannic acid; epigallocatechin and natural extracts containing it; olive leaf extracts; tea extracts, especially green tea; anthocyanins; rosemary extracts; phenolic acids, in particular chorogenic acid; stilbenes, in particular resveratrol; sulfur-containing amino acid derivatives, in particular S-carboxymethylcysteine; ergothioneine; N-acetylcysteine; chelating agents such as N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; carotenoids such as crocetin; and various raw materials such as the mixture of arginine, histidine ribonucleate, mannitol, adenosinetriphosphate, pyridoxine, phenylalanine, tyrosine and hydrolysed RNA marketed by Serobiological Laboratories under the trade name CPP LS 2633-12F®, the water soluble fraction of corn marketed by the company SOLABIA under the trade name Phytovityl®, the mixture of fumitory extract and lemon extract marketed under the name Unicotrozon C-49® by the company Induchem, and the mixture of extracts of ginseng, apple , peach, wheat and barley sold by the company PROVITAL under the trade name Pronalen Bioprotect®. As "scavengers of mono- or polycyclic aromatic compounds" usable in the composition according to the invention, mention may in particular be made of tannins such as ellagic acid; indole derivatives, in particular indol-3-carbinol; tea extracts especially green tea, extracts of water hyacinth or eichornia crassipes; and the water-soluble corn fraction marketed by SOLABIA under the trade name Phytovityl®. Finally, as "heavy metal scavenger agents" that may be used in the composition according to the invention, mention may in particular be made of chelating agents such as EDTA, the pentasodium salt of ethylenediamine tetramethylene phosphonic acid, and N, N'-bis- (3,4,5-trimethoxybenzyl) ethylenediamine or a salt thereof, metal complexes or esters; phytic acid; chitosan derivatives; tea extracts, especially green tea; tannins such as ellagic acid; sulfur-containing amino acids such as cysteine; water hyacinth (Eichornia crassipes) extracts; and the water-soluble corn fraction marketed by SOLABIA under the trade name Phytovityl®. The "anti-radical agents" that can be used in the composition according to the invention comprise, in addition to certain anti-pollution agents mentioned above, vitamin E and its derivatives such as tocopheryl acetate; bioflavonoids; coenzyme 010 or ubiquinone; certain enzymes such as catalase, superoxide dismutase, lactoperoxidase, glutathione peroxidase and quinone reductases; glutathione; benzylidene camphor; benzylcyclanones; substituted naphthalenones; pidolates; phytantriol; gamma-oryzanol; lignans; and melatonin.

By "desquamating agent" is meant any compound capable of acting: either directly on the desquamation by promoting exfoliation, such as the R-hydroxy acids, in particular salicylic acid and its derivatives (of which the acid n- 5-salicylic octanoyl); α-hydroxy acids, such as glycolic, citric, lactic, tartaric, malic or mandelic acids; urea; gentisic acid; oligofucoses; cinnamic acid; Saphora japonica extract; resveratrol; or on the enzymes involved in the desquamation or degradation of corneodesmosomes, such as glycosidases, stratum corneum chymotryptic enzyme (SCCE) or even other proteases (trypsin, chymotrypsin-like). Mention may be made of the chelating agents for mineral salts: EDTA; N-acyl-N, N ', N', ethylene diaminetriacetic acid; aminosulfonic compounds and in particular N- (2-hydroxyethyl) piperazine-N'-2-ethanesulfonic acid (HEPES); 2-oxothiazolidine-4-carboxylic acid derivatives (procysteine); glycine-type alpha amino acid derivatives (as described in EP-0 852 949, as well as the sodium methyl glycine diacetate marketed by BASF under the trade name TRILON M); honey ; sugar derivatives such as O-octanoyl-6-D-maltose and N-acetyl glucosamine. Preferably, the composition according to the invention does not comprise a hydroxylated diphenyl methane derivative of formula (I), in which: R 1 is chosen from a hydrogen atom, a methyl group, a linear or branched alkyl chain, saturated or unsaturated, having 2 to 4 carbon atoms, an -OH group, and a halogen, R2 is selected from a hydrogen atom, a methyl group, a linear or branched alkyl chain, saturated or unsaturated, having from 2 to 5 carbon atoms, R3 is chosen from a methyl group or a linear or branched, saturated or unsaturated alkyl chain having from 2 to 5 carbon atoms, R4 and R5 are independently of one another chosen from an atom of hydrogen, a methyl group, a saturated or unsaturated, linear or branched alkyl chain having from 2 to 5 carbon atoms, an -OH or a halogen group, or any of the hydroxylated diphenyl methane derivatives as described in the patent application FR2900046. The following examples illustrate the present invention. In particular, those skilled in the art will be able to evaluate the expression of the collagen IV, collagen VII and lumicane protein markers by any appropriate method, other than that described hereinafter. EXAMPLES Example 1 Effects on the Expression of the Collagen IV, Collagen VII and Lumicane Protein Markers in a Reconstructed Skin Model The in vitro effects of the two active agents, Aphanizomenon flos-aquae extract (Lanablue® available from Unipex Innovations Inc.) and the extract of Laminaria ochroleuca (Laminaïne Marine® BG / PF marketed by the company BiotechMarine), or their combination, was evaluated on markers involved in the dermoepidermal junction: the collagens IV and VII, and a marker of the extracellular matrix, the lumicane glycoprotein. For this, we used a reconstructed skin model systemically treated with the test compounds, their combination and the reference compound, and evaluated by immunostaining in situ the modulation of protein markers (collagen IV, collagen VII and lumicane).

Procedure Reconstructed skin In vitro reconstructed skin comprising a stratified and differentiated epidermis with horny layers and a living equivalent dermis are made with normal human keratinocytes and normal human dermis fibroblasts according to Bernerd and Asselineau, Cell Death Differ. 1998, 5: 792-802.

Briefly, equivalent dermas are made with bovine collagen I colonized by human dermis fibroblasts. Normal keratinocytes are inoculated after contraction of the lattices. At the end of the culture period, the skins have a morphology very close to normal human skin. They can then be used for different experiments by maintaining the culture medium under the skin that is nourished by capillarity. Treatment of reconstructed skin Aphanizomenon flos-aquae extract (Lanablue® available from Unipex Innovations Inc.) and Laminaria ochroleuca extract (Laminaïne Marine® BG / PF marketed by BiotechMarine), or their association, was evaluated by addition to the culture medium. Analysis of Protein Markers After treatment of reconstructed skin, these were frozen. Cross sections were made by cryostat. For each of the markers, one slide per sample was labeled in immunofluorescence (antibodies against, respectively, Collagen IV: Dako M0785, Collagen VII: Millipore MAB 1345, Lumican R & D Systems AF2846). A negative control (without primary antibody) was performed on the control sample (Tem1). A positive control on normal human skin (PHN) was also performed to validate the antibodies used. Cryocuts were fixed with acetone / methanol and dried at room temperature. After saturation in PBS-Tween (PBS-T), 5% milk, the slides were incubated for 1 hour with the primary antibody solution directed against the protein of interest. After washes, the fixed primary antibodies were revealed by suitable fluorescent secondary antibodies (collagens IV and VII: Fisher 11001 and lumicane: Fisher A11078) and the nuclei of the cells were stained with the propidium iodide fluorescent dye. The slides were washed in PBS-T and mounted in "Fluorescent Mounting Medium" medium (DAKO). The sections were observed using a NIKON E400 microscope. Digital images were recorded with a NIKON DS-Ri1 camera and NISlements software 3.10.35 Lumicane Results Aphanizomenon flos-aquae extract tested alone showed no effect on lumicane protein marker expression. Similarly, the Laminaria ochroleuca extract tested alone showed no effect on the expression of this marker. Surprisingly and remarkably, tested in combination, the active ingredients extracted from Aphanizomenon flos-aquae and Laminaria ochroleuca induce a stimulation of lumicane expression at the level of the epidermis and more moderately at the level of the dermis.

Collagen IV The Aphanizomenon flos-aquae extract tested alone showed no effect on the expression of the collagen IV protein marker. Similarly, laminaria ochroleuca extract tested alone showed no effect on the expression of this marker.

Surprisingly and remarkably, tested in combination, the active ingredients extracted from Aphanizomenon flos-aquae and Laminaria ochroleuca induce a stimulation of the expression of collagen IV mainly at the level of the dermo-epidermal junction and more moderately at the dermis level. .

Collagen VII The Aphanizomenon flos-aquae extract tested alone showed no effect on the expression of the collagen VII protein marker. Similarly, the Laminaria ochroleuca extract tested alone showed no effect on the expression of this marker. Surprisingly and remarkably, tested in combination, the active ingredients extracted from Aphanizomenon flos-aquae and Laminaria ochroleuca induce a stimulation of the expression of collagen VII mainly at the level of the dermo-epidermal junction and more moderately at the level of the dermis. The combination of the two active ingredients, Aphanizomenon flos-aquae extract and Laminaria ochroleuca extract, in comparison with each of the active ingredients alone, has a synergistic effect on the increase of the expression of the collagen IV, collagen VII and lumican protein markers. in reconstructed skins. On the basis of the results obtained, this combination of active agents thus makes it possible to improve cutaneous cohesion and the biomechanical quality of the skin. Example 3 Composition of an Anti-Aging Serum (Fluid O / W Emulsion) Phase Trade name INCI Name Concentration A Water Qsp 100 A Disolvine Na2 (AKZO) Disodium EDTA 0.15 A Nikkol lecinol S10 (Nikko) Hydrogenated lecithin 0.5 A Sepicide LD (seppic) Phenoxyethanol 0.7 A Dow Corning 2501 Cosmetic Wax (Dow Corning) BIS-PEG-18 Methyl ether dimethyl silane 3 A Glycerin 4810 (Oleon) Glycerin 7 A Glucam E-20 Humectant (Lubrizol) Methyl Gluceth-20 2 A Marine Laminate BG / PF (Biotechmarine) Laminaria ochroleuca extract 0.5 A Lanablue ® (Unipex Innovations) Extract of 5 Aphanizomenon flos aquae B Synthalen K (3V) Carbomer 0.3 B Hostacerin® AMPS (Clariant) Ammonium 0.2 polyacryloyldimethyl taurate C Cristalhyal (Soliance) Sodium Hyaluronate 0.1 D Sodium Hydroxide (Chlorenchima ) Sodium Hydroxide 0.09 E Xiameter PMX-200 Silicon e Fluid 5CS Dimethicone 5CS (Dow Corning) F Surfin Ethyl Alcohol 99.9 Alcohol 5 Denature (France Alcohols) Procedure: - Heat all the components of phase A to 75 ° C with stirring, -Disperse with stirring the gels of the phase B until a homogeneous preparation is obtained, -cooling at 40 ° C. and adding, with stirring, the phase C, at -40 ° C. introduce the phase D dissolved beforehand in a little distilled water, stirring until to obtain a smooth and homogeneous gelling, -Chill at 25 ° C / 30 ° C is introduced with stirring phases E and F, and -Chill the mixture at 25 ° C.

Claims (9)

1. A cosmetic treatment process intended to reduce and / or delay the signs of aging of the skin, characterized in that an effective amount of an extract of Laminaria ochroleuca and an extract of Aphanizomenon flos-aquae is applied. , on the skin. 2. A process according to claim 1, intended to reduce and / or delay the signs of photoaging of the skin. 3. A method according to claim 1 or 2, for decreasing and / or delaying wrinkles and fine lines, and / or thinning of the skin, and / or loosening of the skin and / or improving the density of the skin. skin. 4. A process according to any one of claims 1 to 3, characterized in that the Laminaria ochroleuca extract and the Aphanizomenon flos-aquae extract are formulated in a composition further comprising a cosmetically acceptable medium. 5. A process according to claim 4, characterized in that the Laminaria ochroleuca extract is present in the composition in a content of 0.001 to 10% by weight of extract, relative to the total weight of the composition. 6. A process according to claim 4 or 5, characterized in that the Laminaria ochroleuca extract is present in the composition in a content of 0.005 to 5% by weight of extract, relative to the total weight of the composition. 7. A process according to any one of claims 4 to 6, characterized in that the Aphanizomenon flos-aquae extract is present in the composition in a content of 0.001 to 20% by weight of extract, relative to total weight of the composition. 8. A process according to any one of claims 4 to 7, characterized in that the extract of Aphanizomenon flos-aquae is present in the composition in a content of 0.01 to 6% by weight of extract, by relative to the total weight of the composition. 9. A process according to any one of claims 4 to 8, characterized in that the weight ratio between the Laminaria ochroleuca extract and the Aphanizomenon flos-aquae extract is from 0.1 to 10.